Four things to know:
1. Dr. Klaas is a board-certified neurosurgeon from the University of Groningen in the Netherlands.
2. Oncopeptides focuses on the development of therapies for hematological cancers.
3. Dr. Klaas has a PhD in immune-hematology and has authored over 40 publications in international peer-reviewed journals.
4. He replaces Johan Harmenberg as CMO, who will remain as a member of the company’s medical team.
More articles on devices:
Dr. Adam Bruggeman: A spine surgeon’s most important OR trait and bundled benchmarks in spine
Optim Orthopedics welcomes Dr. Thomas Niemeier
7 hospitals expanding spine, neurosurgery programs
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
